Gilead Sciences, Inc. (GILD) स्टॉक विश्लेषण

कंपनी का अवलोकन

Gilead Sciences, Inc. operates as a biopharmaceutical entity focused on discovering, developing, and commercializing medicines to address unmet medical needs across the United States, Europe, and international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - General industry, which implies a reliance on extensive research and development cycles alongside regulatory compliance. Its operational scale is substantial, evidenced by a market capitalization of $176.36B, annual revenue of $29.44B, and a workforce comprising 17000 employees. These valuation and revenue figures indicate that the company holds a significant position in the pharmaceutical landscape, commanding a large market share and possessing the resources to sustain long-term development pipelines for its portfolio of HIV treatments like Biktarvy and Descovy.

वित्तीय स्वास्थ्य

Gilead Sciences, Inc. reported a trailing twelve-month revenue of $29.44B and generated a net income of $8.51B, while achieving an EBITDA of $14.58B. The substantial difference between the revenue of $29.44B and the net income of $8.51B reveals a cost structure where approximately 71.1% of top-line revenue is consumed by operating expenses, taxes, and interest before reaching the bottom line. The company generated free cash flow of $7.54B, which signifies strong financial flexibility to fund capital expenditures, repay debt obligations, or pursue strategic acquisitions without relying heavily on external financing. Profitability is further highlighted by a gross margin of 78.8%, an operating margin of 37.4%, and a profit margin of 28.9%, indicating highly efficient production processes and effective cost management relative to pricing power. On the balance sheet, the company holds $9.61B in cash against $25.54B in debt, resulting in a debt-to-equity ratio of 112.92%, which suggests a leveraged capital structure rather than a conservative one. Short-term liquidity is supported by a current ratio of 1.55, indicating that current assets are 1.55 times greater than current liabilities, ensuring the ability to meet short-term obligations. Management effectiveness is demonstrated by a return on equity of 40.7% and a return on assets of 12.5%, metrics that reveal the company generates substantial profits relative to the shareholders' equity and its total asset base.

मूल्यांकन आकलन

The stock carries a trailing P/E ratio of 20.96 and a forward P/E of 14.78, where the significant difference implies that the market expects earnings growth in the future that will bring the valuation multiple down from current historical levels. A price-to-book ratio of 7.77 indicates that the market values the company at a substantial premium over its book value, reflecting the high value of its intangible assets such as patents and intellectual property. Alternative valuation metrics include a price-to-sales ratio of 5.99 and an EV/EBITDA of 13.19, which suggest that the company is priced at a premium relative to its sales and enterprise value compared to earnings before interest, taxes, depreciation, and amortization. The 52-week trading range spans from a low of $93.37 to a high of $157.29, providing a historical context for price volatility and investor sentiment over the last year. With a beta of 0.40, the stock exhibits price volatility that is significantly lower than the broader market, suggesting it may act as a defensive holding during periods of equity market turbulence.

Growth & Income

The company experienced a revenue growth of 4.7% year-over-year alongside an earnings growth of 23.4% year-over-year. The fact that earnings growth of 23.4% is substantially faster than revenue growth of 4.7% implies that the company is improving its operational efficiency or benefiting from pricing power and margin expansion rather than solely relying on volume increases. As a dividend payer, Gilead Sciences offers a dividend yield of 2.3% with a payout ratio of 46.6%. The payout ratio of 46.6% is considered sustainable given the company's robust earnings growth and strong free cash flow generation, allowing it to maintain or potentially increase dividends while retaining capital for reinvestment. The overall growth and income profile presents a hybrid characteristic of steady top-line expansion coupled with accelerating profitability and a reliable income stream for shareholders.